ChinaBio Today -- The deals in China life science last week weren’t game-changers – there wasn’t any development that even remotely approached the $100 million mark or significantly altered the business landscape. Instead, what we saw was incremental advances, the slow accumulation of change in search of growth as the life science sector matures.
